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The DiGeorge syndrome (DGS) is a developmental field
defect involving varying degrees of maldevelopment of the
thymus, parathyroid glands, aortic arch and cardiac outflow
tract, all derivatives of the third and fourth pharyngeal pouches
known to receive migrating neural crest cells (1). The first step
toward identification of the molecular etiology of this condi-
tion was made in 1981 when de la Chapelle described a
cytogenetically detectable deletion of the short arm of chro-
mosome 22 in a patient with DGS (2). Subsequently, with the
progress of mapping of this chromosome, small deletions not
detectable by cytogenetic techniques were identified by Scam-
bler et al. (3) and Driscoll et al. (4). A short time later,
identical deletions were demonstrated in patients with velocar-
diofacial syndrome (VCFS), providing an explanation for the
frequent phenotypic overlap of patients with DGS and VCFS
(5,6). The unifying acronym, CATCH-22, was coined to em-
phasize the phenotypic components (Cardiac defects, Abnor-
mal facies, Thymus, Cleft palate, Hypocalcemia) and their
shared association with deletions of 22q11. Since then, the
search for responsible genes within the deleted region of
chromosome 22 has been complicated by the size of the
smallest region of deletion overlap (5 3 105 base pairs, the
so-called critical region). While a number of genes have been
identified in the deleted region, none has yet emerged as an
adequate candidate for causation of the phenotype. Unfortu-
nately, the syntenic region of the mouse genome is quite
different from the human (7,8), slowing and perhaps limiting
progress that might be made with mouse genetic techniques. If
more than one gene from within the region is involved in the
pathogenesis of heart defects, it is likely to be years before the
molecular pathogenesis of these malformations is understood.
The search nonetheless is essential because it is likely that
smaller mutations in a gene (or genes) located within the
critical region are involved in the molecular pathogenesis of
isolated conotruncal heart defects.
Fluorescent in situ hybridization analysis and conotruncal
malformations. The development of fluorescent in situ hy-
bridization (FISH) techniques for identifying the presence of
specific DNA sequences in metaphase chromosomes has facil-
itated the rapid diagnosis of 22q11 deletions and made feasible
screening of large numbers of patients with congenital heart
defects. The report in this issue by Goldmuntz et al. (9) is the
largest series of patients with conotruncal malformations to be
studied thus far and, as such, makes an important contribution
toward understanding the incidence of these deletions in
patients with conotruncal malformations. The prospective de-
sign and large size of this study minimized ascertainment bias
in patient selection and for the first time allowed assignment of
meaningful confidence intervals for the frequency of deletion
in children with specific conotruncal lesions. In addition, the
authors identified aortic arch abnormalities as an independent
predictor of deletion. Thus, the deletion is carried by 50% of
patients with interrupted aortic arch, 35% of patients with
truncus arteriosus, 33% with posterior malalignment ventricu-
lar septal defect (VSD) (without aortic interruption) and 16%
with tetralogy of Fallot, while none of 45 patients with trans-
position of the great arteries carried the deletion. For non-
transposition conotruncal defects, the presence of a right aortic
arch, or any arch vessel anomaly, independently increased the
likelihood of finding a deletion.
It might be hoped that this analysis would identify a subset
of patients with conotruncal malformations free of risk for
deletion so that these patients might be excluded from ongoing
screening. Patients with transposition complexes appear to be
such a group. Among the other patients, the lowest risk was
found in patients with tetralogy of Fallot and a normal left
aortic arch. Unfortunately, this large subgroup still has an 8%
risk of deletion, and hence needs to be included if screening of
the conotruncal defect population is to be considered. Because
associated noncardiac findings were not reported, we still do
not know if their presence is correlated with 22q11 deletion in
the study population or whether they might be used to guide
genetic screening (10).
To screen or not to screen? Based on their reported
findings, the authors recommend routine screening for 22q11
deletions in neonates with interrupted aortic arch, truncus
arteriosus, tetralogy of Fallot and posterior malalignment
VSD. The rationale for this recommendation is the association
of the deletion with developmental disorders, feeding difficul-
ties, hypocalcemia, speech pathology and immune deficits,
each of which may not be apparent in neonates. A similar
conclusion was reached by Johnson et al. (10) based on the
smaller prospective study of Webber et al. (11).
We differ in our approach to these patients and believe that
large-scale screening of patients with conotruncal malforma-
tions for 22q11 deletions is not yet indicated. Our approach is
dictated by the absence of evidence that presence of a 22q11
deletion is predictive of outcome in patients with conotruncal
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defects. Specifically, the phenotypic spectrum of patients car-
rying these deletions is wide, and it is unknown whether the
presence of 22q11 deletions is independently predictive of
associated medical or psychological problems, developmental
potential or cardiovascular outcome in patients with conotrun-
cal malformations. Nonetheless, families frequently are given a
“doom and gloom” outlook for these children, especially with
respect to neurologic development. We have spent many hours
conveying the uncertainty that surrounds this test to families of
children with 22q11 deletions in conjunction with what appears
to be an isolated conotruncal malformation, who nonetheless
have been counseled that the deletion will lead to mental
retardation.
The catch: does deletion predict worse outcomes? To date
there is very little information about the cardiovascular, neu-
rodevelopmental or immunologic outcome of patients with
these deletions. The best estimates of outcome are provided by
a retrospective, questionnaire-based study of over 500 Euro-
pean patients with 22q11 deletions (12). Eight percent of these
patients died, with all but one death due to congenital heart
disease, and 86% of deaths occurred before age 6 months.
Development was normal in 32% of patients, was mildly
delayed in 30%, moderately delayed in 15% and severely
delayed in only 3%. The developmental outcome in the
remaining 20% was unspecified, but given the study design,
these patients were likely to be at the mild end of the spectrum
because severe outcomes were more likely to be reported. For
children with the deletion, 9% had behavioral or psychological
problems, while 6.5% of adults with the deletion had at least
one episode of psychosis. Infectious complications were rare,
with less than 1% reporting major problems with infection.
Hypocalcemia was common, with 60% reporting some evi-
dence of hypocalcemia. In most patients hypocalcemia had
resolved. While there was no control group for comparison,
this study suggests that, with the exception of hypocalcemia,
outcomes may be similar to those in an unselected population
with conotruncal defects. In our estimation the unproven
ability of this test to predict outcomes severely limits its use as
a screening tool. Until it is shown through a prospective study
that outcomes are different for deleted and nondeleted pa-
tients with conotruncal malformations, FISH analysis of 22q11
deletions remains a research tool.
It is clear that not all patients with DGS or VCFS pheno-
types carry 22q11 deletions (11,13), and it is uncertain whether
all patients with the deletion will have noncardiac manifesta-
tions of these syndromes. As a result, it is our opinion that
patients without the deletion need the same careful clinical
evaluation and observation as patients who carry deletions. We
recommend phenotypic evaluation including measurement of
serum calcium, T cell subsets, and evaluation by a dysmor-
phologist for patients with interrupted arch, truncus arteriosus
and tetralogy of Fallot when the arch is abnormal or the infant
is dysmorphic. For all patients with conotruncal malformations
we recommend follow-up with careful attention to issues of
possible developmental or speech delay.
What about the utility of this test to guide genetic counsel-
ing for parents of a child with a conotruncal malformation? In
80% of patients the deletion arises de novo, so the recurrence
risk in these families is that of other patients with a single
affected child, approximately 1% to 3% (14). For those parents
who carry the deletion the test may have more value, but how
should one counsel these parents? Although there is a 50%
chance that the deletion would be inherited by the child of such
a parent, what that predicts about the outcome of that child is
uncertain. Again, the best information to date comes from
Ryan et al. (12). In 35 patients of 27 parents carrying the
deletion, the child’s heart defect was worse than the parent’s in
77%, as might be expected, since more severely affected
patients may not have survived to reproductive age 20 or more
years ago. As important, the developmental outcome for
children with inherited deletions was the same or better than
their affected parent in 8 of 17 cases and worse in 9. Notably,
developmental delay was only mild in eight of the nine children
with worse developmental outcome than their affected parent.
Therefore, this test may be most useful for determining the risk
(but not the outcome) of congenital heart disease in future
siblings of a proband with a conotruncal defect. For parents
carrying the deletion who would terminate a pregnancy if a
second child were affected, prenatal FISH analysis and/or fetal
echocardiography can be used to guide this decision.
Genetic testing is not without its own risks in modern
society. It is not far-fetched to be concerned that information
about a patient’s deletion status ultimately could be used by
insurance companies to deny coverage for mental illness,
infectious diseases or complications arising from craniofacial
abnormalities. Nor is it beyond the realm of possibility that
employers might discriminate against patients with deletions in
making hiring decisions. Until all Americans are protected by
legislation forbidding genetic discrimination, these risks are
real and are only exacerbated by the paucity of outcomes
information about these patients. While such risks are war-
ranted when the results of genetic testing direct treatment or
accurately predict outcome, the risk may not yet be warranted
in patients with conotruncal malformations.
We encourage pediatric cardiologists to read the recom-
mendations of Johnson et al. (10) and Goldmuntz et al. (9),
and make up their own minds. We believe strongly that
pediatric cardiologists should participate in the genetic coun-
seling of these patients. As cardiologists, we have important
information about the outcomes of cardiac surgery for
conotruncal malformations in our communities that may not
be known to geneticists, and because we are involved in the
Abbreviations and Acronyms
CATCH-22 5 cardiac defects, abnormal facies, thymus, cleft
palate, hypocalcemia
DGS 5 DiGeorge syndrome
FISH 5 fluorescent in situ hybridization
VCFS 5 velocraniofacial syndrome
VSD 5 ventricular septal defect
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long-term care of these patients, we are ideally positioned to
help patients and parents understand and live with the com-
plications and uncertainties that now come with conotruncal
defects. To play this role, the pediatric cardiologist must be
clear in his or her own mind about the rationale for testing or
not testing, must understand the basic genetics of these
syndromes, and must keep abreast of the rapidly advancing
literature in this field. The role of the pediatric cardiologist in
genetic counseling will grow rapidly in the coming years as the
molecular basis of an increasing number of congenital heart
lesions becomes known. If we fail to participate now, we risk
failing our patients at this critical time in the history of
congenital heart disease.
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